Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics director Charles Dockendorff will not stand for re-election in 2026

Neutral Impact 2 of 5 leadership Written later

Haemonetics director Charles J. Dockendorff told the company on April 27, 2026 that he will not stand for re-election at the 2026 Annual Meeting of Shareholders. He will remain a director and keep his Audit and Governance and Compliance Committee roles until that meeting, and the filing says the decision is not the result of any disagreement with the company.

Key points

  • Charles J. Dockendorff informed the company on April 27, 2026 of his decision
  • He has served on the Board since 2014 and sits on the Audit Committee and Governance and Compliance Committee
  • He will serve until the 2026 Annual Meeting of Shareholders
  • The filing states the decision is not the result of any disagreement with the company

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECMay 1, 2026, 4:18 PM ET
Accession number0000313143-26-000023

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.